- Home
- FISI vs CTNM Comparison
FISI vs CTNM Comparison
Compare FISI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- CTNM
- Stock Information
- Founded
- FISI 1817
- CTNM 2009
- Country
- FISI United States
- CTNM United States
- Employees
- FISI N/A
- CTNM N/A
- Industry
- FISI Major Banks
- CTNM
- Sector
- FISI Finance
- CTNM
- Exchange
- FISI Nasdaq
- CTNM Nasdaq
- Market Cap
- FISI 416.4M
- CTNM 363.2M
- IPO Year
- FISI 1999
- CTNM 2024
- Fundamental
- Price
- FISI $27.90
- CTNM $14.18
- Analyst Decision
- FISI Hold
- CTNM Strong Buy
- Analyst Count
- FISI 2
- CTNM 4
- Target Price
- FISI $22.00
- CTNM $29.25
- AVG Volume (30 Days)
- FISI 43.5K
- CTNM 81.0K
- Earning Date
- FISI 10-24-2024
- CTNM 11-06-2024
- Dividend Yield
- FISI 4.30%
- CTNM N/A
- EPS Growth
- FISI N/A
- CTNM N/A
- EPS
- FISI 3.17
- CTNM N/A
- Revenue
- FISI $216,605,000.00
- CTNM N/A
- Revenue This Year
- FISI N/A
- CTNM N/A
- Revenue Next Year
- FISI $6.94
- CTNM N/A
- P/E Ratio
- FISI $8.80
- CTNM N/A
- Revenue Growth
- FISI 9.25
- CTNM N/A
- 52 Week Low
- FISI $16.29
- CTNM $12.33
- 52 Week High
- FISI $28.14
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- FISI 62.80
- CTNM N/A
- Support Level
- FISI $26.00
- CTNM N/A
- Resistance Level
- FISI $28.12
- CTNM N/A
- Average True Range (ATR)
- FISI 0.74
- CTNM 0.00
- MACD
- FISI 0.09
- CTNM 0.00
- Stochastic Oscillator
- FISI 93.85
- CTNM 0.00
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.